Skip to main content

Table 2 The association between co-expression of SALL4/ALDH1A1 and clinicopathological parameters of serous ovarian carcinoma (SOC) samples (Intensity of staining and H-score) (P value; Pearson’s χ2 test)

From: Co-expression of cancer stem cell markers, SALL4/ALDH1A1, is associated with tumor aggressiveness and poor survival in patients with serous ovarian carcinoma

Patients and tumor characteristics

Total

samples

N (%)

SALL4/ALDH1 phenotypes

P-value

SALL4 Low /ALDH1A1 Low

SALL4 Low /ALDH1A1 High

SALL4 High /ALDH1A1 Low

SALL4 High /ALDH1A1 High

OSC

45 (100.0)

19 (42.2)

14 (31.1)

6 (13.3)

6 (13.3)

Mean age, years (Range)

45 (16-74)

     

 ≤Mean age

19 (42.2)

7 (36.8)

5 (35.7)

2 (33.3)

5 (83.3)

0.185

 >Mean age

26 (57.8)

12 (63.2)

9 (64.3)

4 (66.7)

1 (16.7)

Mean tumor size (cm)

8.28

     

 ≤Mean

25 (55.6)

11 (78.6)

9 (75.0)

3 (75.0)

2 (33.3)

0.215

 >Mean

11 (24.4)

3 (21.4)

3 (25.0)

1 (25.0)

4 (66.7)

 Not identified

9 (20.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Histological grade

 I

20 (44.4)

9 (47.4)

7 (50.0)

0 (0.0)

4 (66.7)

0.359

 II

4 (8.9)

2 (10.5)

1 (7.1)

1 (16.7)

0 (0.0)

 III

21 (46.7)

8 (42.1)

6 (42.9)

5 (83.3)

2 (33.3)

 IV

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

FIGO stage

 I

10 (22.2)

5 (26.3)

3 (21.4)

0 (0.0)

2 (33.3)

0.047

 II

15 (33.3)

5 (26.3)

7 (50.0)

0 (0.0)

3 (50.0)

 III

20 (44.4)

9 (47.4)

4 (28.6)

6 (100.0)

1 (16.7)

 IV

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Lymph node (LN) metastasis

 Involved

20 (44.4)

9 (50.0)

6 (50.0)

2 (33.3)

3 (50.0)

0.903

 None

22 (48.9)

9 (50.0)

6 (50.0)

4 (66.7)

3 (50.0)

 Not identified

3 (6.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Vascular invasion (VI)

 Involved

5 (11.1)

1 (5.6)

1 (8.3)

2 (33.3)

1 (16.7)

0.309

 None

37 (82.2)

17 (94.4)

11(91.7)

4 (66.7)

5 (83.3)

 Not identified

3 (6.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Omentum

 Involved

9 (20.0)

5 (27.8)

1 (8.3)

2 (33.3)

1 (16.7)

0.524

 None

33 (73.3)

13 (72.2)

11 (91.7)

4 (66.7)

5 (83.3)

 Not identified

3 (6.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Fallopian tube

 Involved

9 (20.0)

4 (22.2)

3 (25.0)

2 (33.3)

0 (0.0)

0.524

 None

33 (73.3)

14 (77.8)

9 (75.0)

4 (66.7)

6 (100.0)

 Not identified

3 (6.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Cervix

 Involved

8 (17.8)

5 (27.8)

1 (8.3)

2 (33.3)

0 (0.0)

0.263

 None

34 (75.6)

13 (72.2)

11 (91.7)

4 (66.7)

6 (100.0)

 Not identified

3 (6.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Endometrium

 Involved

5 (11.1)

3 (16.7)

1 (8.3)

1 (16.7)

0 (0.0)

0.688

 None

37 (82.2)

15 (83.3)

11 (91.7)

5 (83.3)

6 (100.0)

 Not identified

3 (6.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Myometrium

 Involved

6 (13.3)

3 (16.7)

1 (8.3)

1 (16.7)

1 (16.7)

0.922

 None

36 (80.0)

15 (83.3)

11 (91.7)

5 (83.3)

5 (83.3)

 Not identified

3 (6.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Vagina

 Involved

10 (22.2)

3 (16.7)

3 (25.0)

3 (50.0)

1 (16.7)

0.399

 None

32 (71.1)

15 (83.3)

9 (75.0)

3 (50.0)

5 (83.3)

 Not identified

3 (6.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Peritoneum

 Involved

3 (6.7)

2 (10.5)

1 (8.3)

0 (0.0)

0 (0.0)

0.728

 None

40 (88.9)

17 (89.5)

11 (91.7)

6 (100.0)

6 (100.0)

 Not identified

2 (4.4)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Lymphovascular space invasion

 Involved

8 (17.8)

4 (21.1)

3 (25.0)

1 (16.7)

0 (0.0)

0.618

 None

35 (77.8)

15 (78.9)

9 (75.0)

5 (83.3)

6 (100.0)

 Not identified

2 (4.4)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Perineural invasion

 Present

3 (6.7)

0 (0.0)

2 (16.7)

1 (16.7)

0 (0.0)

0.230

 Absent

39 (86.7)

18 (100.0)

10 (83.3)

5 (83.3)

6 (100.0)

 Not identified

3 (6.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Colon

 Involved

10 (22.2)

4 (22.2)

3 (23.1)

3 (50.0)

0 (0.0)

0.237

 None

33 (73.3)

14 (77.8)

10 (76.9)

3 (50.0)

6 (100.0)

 Not identified

2 (4.4)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Small intestine

 Involved

4 (8.9)

3 (16.7)

1 (8.3)

0 (0.0)

0 (0.0)

0.503

 None

38 (84.4)

15 (83.3)

11 (91.7)

6 (100.0)

6 (100.0)

 Not identified

3 (6.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Post-cul-de-sac

 Involved

7 (15.6)

5 (27.8)

0 (0.0)

2 (33.3)

0 (0.0)

0.094

 None

35 (77.8)

13 (72.2)

12 (100.0)

4 (66.7)

6 (100.0)

 Not identified

3 (6.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Paracolic lymph node

 Involved

5 (11.1)

4 (22.2)

1 (8.3)

0 (0.0)

0 (0.0)

0.309

 None

37 (82.2)

14 (77.8)

11 (91.7)

6 (100.0)

6 (100.0)

 Not identified

3 (6.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Distant metastasis

 Present

20 (44.4)

6 (31.6)

6 (42.9)

6 (100.0)

2 (33.3)

0.028

 Absent

25 (55.6)

13 (68.4)

8 (57.1)

0 (0.0)

4 (66.7)

Tumor recurrence

 Yes

25 (55.6)

10 (52.6)

6 (42.9)

6 (100.0)

3 (50.0)

0.119

 No

20 (44.4)

9 (47.4)

8 (57.1)

0 (0.0)

3 (50.0)